IRIS
TROIANI, Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.167
NA - Nord America 6.245
AS - Asia 5.496
SA - Sud America 826
AF - Africa 83
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 3
Totale 25.841
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.742
US - Stati Uniti d'America 6.122
SG - Singapore 1.878
IE - Irlanda 1.236
CN - Cina 1.165
IT - Italia 1.035
HK - Hong Kong 852
VN - Vietnam 683
BR - Brasile 674
DE - Germania 456
GB - Regno Unito 443
UA - Ucraina 352
KR - Corea 314
FR - Francia 269
IN - India 157
FI - Finlandia 139
SE - Svezia 126
JP - Giappone 117
GR - Grecia 109
TR - Turchia 90
CA - Canada 77
NL - Olanda 69
AR - Argentina 59
BD - Bangladesh 45
PK - Pakistan 43
AT - Austria 35
MX - Messico 32
BE - Belgio 30
ID - Indonesia 30
PL - Polonia 29
EC - Ecuador 28
ES - Italia 26
IQ - Iraq 22
ZA - Sudafrica 21
CO - Colombia 20
CZ - Repubblica Ceca 19
MA - Marocco 17
AU - Australia 13
CH - Svizzera 11
AZ - Azerbaigian 10
CL - Cile 10
IL - Israele 10
VE - Venezuela 10
LT - Lituania 9
PH - Filippine 9
IR - Iran 8
NZ - Nuova Zelanda 8
PE - Perù 8
TH - Thailandia 8
TN - Tunisia 8
KE - Kenya 7
PY - Paraguay 7
NP - Nepal 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
BJ - Benin 5
BO - Bolivia 5
EG - Egitto 5
JO - Giordania 5
KG - Kirghizistan 5
SA - Arabia Saudita 5
AL - Albania 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
KZ - Kazakistan 4
MK - Macedonia 4
RO - Romania 4
SN - Senegal 4
UY - Uruguay 4
BY - Bielorussia 3
DZ - Algeria 3
ET - Etiopia 3
MY - Malesia 3
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
GT - Guatemala 2
HN - Honduras 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CY - Cipro 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 25.827
Salva come PNG Salva come JPEG
Città #
Moscow 3.126
Dublin 1.221
San Jose 929
Singapore 850
Hong Kong 836
Santa Clara 745
Chandler 669
Jacksonville 563
Seoul 292
Ashburn 284
Ho Chi Minh City 211
Beijing 203
Naples 195
New York 184
Hanoi 164
Princeton 162
Hefei 160
Dallas 148
Bremen 138
Roxbury 129
Medford 121
Ann Arbor 120
Los Angeles 119
Munich 103
The Dalles 93
Bengaluru 84
Caserta 79
São Paulo 75
Wilmington 72
Boardman 59
Milan 52
Nanjing 48
Cambridge 47
Des Moines 44
San Mateo 43
Da Nang 40
Woodbridge 38
Turku 37
Haiphong 36
Amsterdam 34
Elora 34
Napoli 34
Nuremberg 33
Council Bluffs 30
Brussels 29
Warsaw 27
Houston 25
Rio de Janeiro 25
Brooklyn 24
Dong Ket 22
Orem 22
Tianjin 22
Aversa 21
Atlanta 20
Hải Dương 19
Rome 19
Tokyo 19
Vienna 19
Montreal 18
Shanghai 18
Chicago 17
Falkenstein 17
Mountain View 17
Brno 16
Manchester 16
Brasília 15
Columbus 15
Nanchang 15
Norwalk 15
Chennai 14
Helsinki 14
Frankfurt am Main 13
Hangzhou 13
Jakarta 13
Lappeenranta 13
London 13
Rawalpindi 13
San Francisco 13
Thái Bình 13
Belo Horizonte 12
Changsha 12
Jinan 12
Madrid 12
Bogotá 11
Ercolano 11
Istanbul 11
Piscataway 11
Baku 10
Guangzhou 10
Memphis 10
Seattle 10
Boston 9
Cape Town 9
Curitiba 9
Düsseldorf 9
Guayaquil 9
Hillsboro 9
Mumbai 9
Phủ Lý 9
Toronto 9
Totale 13.521
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 248
Beyond N staging in colorectal cancer: Current approaches and future perspectives 223
ONCOLOGIA MEDICA 206
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 205
AXL is an oncotarget in human colorectal cancer 195
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 195
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 192
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 185
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 184
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 183
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 182
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 181
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 180
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 177
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 174
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 173
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 173
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 172
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 171
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 167
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 163
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 162
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 161
Cytologic diagnosis of metastatic melanoma by FNA: A practical review 161
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 161
Small Bowel Metastasis in a Stage IV Melanoma Patient: A Report of Multimodal Approach 161
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 160
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 159
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 159
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 159
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 158
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 156
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 155
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 154
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 153
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 152
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 151
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 151
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 151
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 150
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 150
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 150
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 149
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 145
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 145
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 145
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 145
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 145
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 144
Pimasertib hydrochloride 143
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 141
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 141
Antiangiogenic drugs in non small cell lung cancer treatment 141
Farmacogenomica e cancro colorettale 139
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 138
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 135
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 135
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review 134
To Get the Most out of the Least: BRAF Molecular Evaluation in Melanoma Metastases on Cell Suspension from Fine Needle Aspiration Cytology Needle Rinses 134
The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors 133
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 132
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 132
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 130
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 130
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 129
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 129
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 129
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 129
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 129
TRASTUZUMAB RESISTANCE IN BREAST CANCER 128
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 128
Application of CytoMatrix for the diagnosis of melanoma metastases on FNA cytology samples: Performance of a novel cell block method 127
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 127
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 125
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 124
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 123
Targeting EGFR in Pancreatic Cancer Treatment. 123
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 123
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 123
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 123
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 123
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 122
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 121
Prevention of cardiovascular complications in elderly cancer patients 121
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 120
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 120
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 120
All for one: Collaboration between dermatologist, radiation oncologist and radiologist in the clinical management of “difficult to treat” non melanoma skin cancer 119
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia 118
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 118
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 118
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 118
Totale 14.843
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202155 0 0 0 0 0 0 0 0 0 0 0 55
2021/20221.163 57 26 27 25 340 25 37 35 57 90 120 324
2022/20232.567 255 56 46 237 283 233 10 158 1.150 14 71 54
2023/20241.111 102 49 40 67 329 171 33 33 21 16 86 164
2024/20253.522 61 93 47 139 527 462 453 328 466 379 308 259
2025/202615.208 609 716 748 734 1.213 8.144 809 791 642 416 260 126
Totale 26.356